Los Angeles Capital Management LLC Trims Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA)

Los Angeles Capital Management LLC decreased its holdings in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) by 17.4% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 28,032 shares of the company’s stock after selling 5,900 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Entrada Therapeutics were worth $485,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. US Bancorp DE purchased a new stake in Entrada Therapeutics during the 3rd quarter valued at approximately $42,000. GSA Capital Partners LLP raised its stake in shares of Entrada Therapeutics by 71.8% during the third quarter. GSA Capital Partners LLP now owns 36,577 shares of the company’s stock worth $585,000 after purchasing an additional 15,284 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Entrada Therapeutics by 132.4% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 138,605 shares of the company’s stock worth $2,215,000 after purchasing an additional 78,953 shares during the last quarter. Massachusetts Financial Services Co. MA acquired a new stake in shares of Entrada Therapeutics during the third quarter worth $1,109,000. Finally, Charles Schwab Investment Management Inc. grew its position in Entrada Therapeutics by 14.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 185,984 shares of the company’s stock valued at $2,972,000 after buying an additional 23,643 shares during the last quarter. Hedge funds and other institutional investors own 86.39% of the company’s stock.

Entrada Therapeutics Stock Down 5.1 %

Shares of TRDA opened at $11.33 on Tuesday. The company has a 50-day simple moving average of $14.18 and a 200-day simple moving average of $16.22. The company has a market capitalization of $423.97 million, a PE ratio of 7.13 and a beta of -0.17. Entrada Therapeutics, Inc. has a 52-week low of $11.28 and a 52-week high of $21.79.

Entrada Therapeutics (NASDAQ:TRDA) last issued its earnings results on Thursday, February 27th. The company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.69. Entrada Therapeutics had a net margin of 25.53% and a return on equity of 16.11%. The company had revenue of $12.25 million during the quarter, compared to analysts’ expectations of $11.95 million. On average, research analysts anticipate that Entrada Therapeutics, Inc. will post 1.12 EPS for the current year.

Analyst Ratings Changes

TRDA has been the subject of a number of analyst reports. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Entrada Therapeutics in a research report on Tuesday, February 25th. Roth Mkm started coverage on shares of Entrada Therapeutics in a report on Thursday, December 5th. They set a “buy” rating and a $29.00 price target for the company. Oppenheimer lifted their price objective on Entrada Therapeutics from $25.00 to $28.00 and gave the company an “outperform” rating in a report on Wednesday, November 6th. Finally, Roth Capital upgraded Entrada Therapeutics to a “strong-buy” rating in a research report on Thursday, December 5th.

Insider Activity at Entrada Therapeutics

In other Entrada Therapeutics news, major shareholder Bioventures 2018 L.P. Mpm sold 22,935 shares of the firm’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $20.77, for a total transaction of $476,359.95. Following the completion of the transaction, the insider now directly owns 4,402,849 shares in the company, valued at approximately $91,447,173.73. This trade represents a 0.52 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 7.59% of the stock is currently owned by company insiders.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.